Drug Development Pipeline
This program is studying CSA-131, a synthetic compound that mimics natural compounds in the body that help fight bacterial and fungal infections. CSA-131 aims to inhibit the growth of bacteria and fungi, break down their biofilms -- protective layers that bacteria and fungi form that make them more difficult to kill with anti-infectives -- and ultimately kill these organisms.
Laboratory studies to develop and test this compound are underway.
This program is sponsored by Kinnear Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More